Literature DB >> 22237669

Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both?

Robert L Avery.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22237669     DOI： 10.1016/j.jaapos.2011.11.002

Source DB:  PubMed          Journal:  J AAPOS        ISSN： 1091-8531            Impact factor:   1.220


× No keyword cloud information.
  20 in total

Review 1.  Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity.

Authors:  Kay D Beharry; Gloria B Valencia; Douglas R Lazzaro; Jacob V Aranda
Journal:  Semin Perinatol       Date:  2016-01-29       Impact factor: 3.300

2.  Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial.

Authors:  Andreas Stahl; Tim U Krohne; Nicole Eter; Isabel Oberacher-Velten; Rainer Guthoff; Synke Meltendorf; Oliver Ehrt; Sabine Aisenbrey; Johann Roider; Heinrich Gerding; Claudia Jandeck; Lois E H Smith; Johanna M Walz
Journal:  JAMA Pediatr       Date:  2018-03-01       Impact factor: 16.193

Review 3.  Insulin-like growth factor-1 and anti-vascular endothelial growth factor in retinopathy of prematurity: has the time come?

Authors:  Andreas Stahl; Ann Hellstrom; Lois E H Smith
Journal:  Neonatology       Date:  2014-10-05       Impact factor: 4.035

Review 4.  Advances in understanding and management of retinopathy of prematurity.

Authors:  Mary Elizabeth Hartnett
Journal:  Surv Ophthalmol       Date:  2016-12-22       Impact factor: 6.048

5.  Vascular Safety of Ranibizumab in Patients With Diabetic Macular Edema: A Pooled Analysis of Patient-Level Data From Randomized Clinical Trials.

Authors:  Marco A Zarbin; Cornelia Dunger-Baldauf; Zdenka Haskova; Prashil Koovejee; Marie-Catherine Mousseau; Philippe Margaron; Howard Snow; Paul E Beaumont; Giovanni Staurenghi; Steven Francom
Journal:  JAMA Ophthalmol       Date:  2017-05-01       Impact factor: 7.389

6.  Treatment outcomes of combination of anti-vascular endothelial growth factor injection and laser photocoagulation in Type 1 ROP and APROP.

Authors:  Parveen Sen; Aditi Ashok Kumar Agarwal; Pramod Bhende; Suganeswari Ganesan
Journal:  Int Ophthalmol       Date:  2021-08-20       Impact factor: 2.031

7.  Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.

Authors:  Maureen G Maguire; Ebenezer Daniel; Ankoor R Shah; Juan E Grunwald; Stephanie A Hagstrom; Robert L Avery; Jiayan Huang; Revell W Martin; Daniel B Roth; Alessandro A Castellarin; Sophie J Bakri; Stuart L Fine; Daniel F Martin
Journal:  Ophthalmology       Date:  2013-05-22       Impact factor: 12.079

Review 8.  Educational paper: do we need neonatal clinical pharmacologists?

Authors:  Karel Allegaert; Jean Paul Langhendries; John N van den Anker
Journal:  Eur J Pediatr       Date:  2012-05-16       Impact factor: 3.183

9.  Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity.

Authors:  Agata Mota; Angela Carneiro; Jorge Breda; Vitor Rosas; Augusto Magalhães; Renato Silva; Fernando Falcão-Reis
Journal:  Case Rep Ophthalmol       Date:  2012-04-30

10.  Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.

Authors:  Gerard P Barry; Yinxi Yu; Gui-Shuang Ying; Lauren A Tomlinson; Juliann Lajoie; Marilyn Fisher; Gil Binenbaum
Journal:  Ophthalmology       Date:  2020-12-31       Impact factor: 14.277
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.